KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Biogen (BIIB) R&D In Process (2017 - 2021)

Biogen (BIIB) has 5 years of R&D In Process data on record, last reported at $18.0 million in Q2 2021.

  • For Q2 2021, R&D In Process changed N/A year-over-year to $18.0 million; the TTM value through Sep 2022 reached $18.0 million, changed 0.0%, while the annual FY2021 figure was $18.0 million, 76.0% down from the prior year.
  • R&D In Process reached $18.0 million in Q2 2021 per BIIB's latest filing, down from $75.0 million in the prior quarter.
  • Across five years, R&D In Process topped out at $120.0 million in Q2 2017 and bottomed at $10.0 million in Q1 2018.
  • Average R&D In Process over 4 years is $57.2 million, with a median of $75.0 million recorded in 2018.
  • The widest YoY moves for R&D In Process: up 37.5% in 2018, down 37.5% in 2018.
  • A 4-year view of R&D In Process shows it stood at $120.0 million in 2017, then crashed by 37.5% to $75.0 million in 2018, then changed by 0.0% to $75.0 million in 2020, then plummeted by 76.0% to $18.0 million in 2021.
  • Per Business Quant database, its latest 3 readings for R&D In Process were $18.0 million in Q2 2021, $75.0 million in Q1 2020, and $75.0 million in Q4 2018.